Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,472 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 18,472 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 20, 2026 00:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002534 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,472 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:58 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001015 · form4.xml · derivative · entry 3 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · derivative.exercise_date: The shares vested monthly over twelve (12) months from the grant date of May 11, 2016. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:58 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 4,000 | $36.36 | $145,440.00 |
DisclosureSEC source: 0000905148-26-001015 · form4.xml · nonDerivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,722 Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:58 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 4,000 | $24.00 | $96,000.00 |
DisclosureSEC source: 0000905148-26-001015 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001934 · form4.xml · derivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-05-23 F3 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001934 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,722 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:21 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000905148-24-001655 · form4.xml · derivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-25 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:21 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001655 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,222 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034285 · form4.xml · derivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034285 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,222 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020308 · form4.xml · derivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020308 · form4.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,222 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005770 · edgar.xml · derivative · entry 2 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005770 · edgar.xml · nonDerivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,222 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:51 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001179110-20-006130 · edgar.xml · derivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:08 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001179110-19-006694 · edgar.xml · derivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-05-23 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 17, 2018 Filed May 19, 2018 01:35 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001179110-18-007152 · edgar.xml · derivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 12, 2017 Filed May 12, 2017 22:02 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001179110-17-007133 · edgar.xml · derivative · entry 1 MOOS WALTER H · CIK 0001190272 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-12 F1 · derivative.exercise_date: The shares vest monthly over twelve (12) months from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.